PRO 140: Phase IIb data

An open-label, U.S. Phase IIb trial showed that once-weekly 350 mg subcutaneous PRO 140 as monotherapy has led to 0 virologic failures, defined as 2 consecutive measurements of HIV-1 RNA levels of >=4...